Abbott Laboratories (NYSE: ABT) reported second-quarter 2021 financial results before the regular market hours on Thursday. The pharmaceutical giant reported Q2 sales of $ 10.2 billion, up 40% year-over-year and higher than the Wall Street projection. Net income of $1.17 per share was also above the target that analysts had anticipated. ABT shares rose 0.4% […]
Abbott Laboratories (NYSE: ABT) reported second-quarter 2021 financial results before the regular market hours on Thursday. The pharmaceutical giant reported Q2 sales of $ 10.2 billion, up 40% year-over-year and higher than the Wall Street projection. Net income of $1.17 per share was also above the target that analysts had anticipated. ABT shares rose 0.4% […]
Abbott Laboratories (NYSE: ABT) reported second-quarter 2021 financial results before the regular market hours on Thursday. The pharmaceutical giant reported Q2 sales of $ 10.2 billion, up 40% year-over-year and higher than the Wall Street projection. Net income of $1.17 per share was also above the target that analysts had anticipated.
ABT shares rose 0.4% immediately following the announcement. The stock has gained 9% since the beginning of this year.
